\
&
Contact us
\
&
Contact us
This was 3 years ago
LocationHybride event - Stockholm, Sweden or Online
ProgrammesEIT Health is organising the EIT Health Summit 2022 in a hybrid format with participants having the possibility to attend either online or in-person in Stockholm (Sweden), hosted by the Karolinska Institute.
The Summit provides healthcare professionals from around 30 countries the opportunity to engage in discussions on how healthcare systems can incorporate and reform new care delivery and financial approaches, to recover from COVID and in view of ensuring their sustainability, resilience and preparedness for future health threats.
In-Person Early bird registration until 14 April at 11:59 pm CET.
Registration deadline 13 May at 11:59 pm CET.
Please note that capacity at the in-person event is limited and that this is a paying event.
More information and registration on the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Digital Europe Cybersecurity Defence
Research Infrastructures Culture and society Climate, Energy, Mobility
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
